Glaukos' iDose TR Meets Primary Endpoint in Phase 4 Trial
Glaukos Corp. announced that its phase 4 trial for the iDose TR (travoprost intracameral implant) met its primary endpoint, demonstrating a reduction in mean diurnal intraocular pressure among patients with open-angle glaucoma or ocular hypertension. The results indicate the effectiveness of the implant as a treatment option. The company is likely to use these findings for further regulatory submissions and commercialization efforts. This outcome supports Glaukos' position in ophthalmic drug delivery systems, potentially enhancing its market presence.
Tickers: $GKOS
Topics: glaucoma treatment intraocular pressure ophthalmology